Bioventrix Inc. acquired Materacor Inc., the developer of a heart failure therapy that uses an injectable alginate-based hydrogel and a minimally invasive endocardial delivery system to restructure the left ventricle and reverse or stop the progression of ischemic or non-ischemic congestive heart failure with reduced ejection faction (HFrEF). The terms of the transaction were not disclosed.

Second Sight Medical Products Inc. has struck a deal to acquire Nano Precision Medical Inc. (NPM) in an all-stock transaction. NPM will merge with a wholly owned subsidiary of Second Sight, and the combined company will focus on the development of drug and device medical implants. The deal comes less than a year after Second Sight’s proposed acquisition of French company Pixium Vision LLC fell through in controversial fashion. The company will issue approximately 134 million shares of its common stock to acquire full ownership of NPM and shareholders will acquire approximately 23% equity of the combined company

The Cooper Companies Inc. plans to acquire the entirety of Cook Medical Inc.’s reproductive health business in this fiscal quarter for $675 million at closing plus $200 million paid in four $50 million annual installments. The acquisition will expand Cooper’s presence in the Asia-Pacific region. The Cook deal will also accelerate Cooper’s labor and delivery medical device efforts by adding 115 people sales, marketing, education and support staff globally.

Combining Sarepta Therapeutics Inc.’s gene editing technology and Genedit Inc.’s Nanogalaxy platform to treat neuromuscular disorders shows promising potential, the companies reported. A year into the research collaboration, Genedit’s polymer nanoparticles have demonstrated the ability to deliver therapeutic cargo to specific muscle tissue following system administration of targeted genetic medicines.

Glooko Inc. acquired Xbird GmbH to further build out its diabetes management platform by adding Xbird’s just-in-time artificial intelligence (JITAI) system to provide adaptive interventions that can enable better informed decision making in the moment. The company declined to provide details of the transaction.

Stockholm-based Alex Therapeutics AB is joining forces with pharmaceutical company Pfizer Inc. to roll out digital therapies to patients in Germany. The partnership will utilize Alex Therapeutics' Alex DTx platform for nicotine addiction in Germany. The platform combines cognitive behavioral therapy (CBT) and acceptance and commitment therapy with artificial intelligence (AI) to create treatments for a wide range of psychiatric and somatic disorders.

Nextkidney BV has signed a deal to buy Dialyss Pte. Ltd. as it gears up to commercialize its home hemodialysis device Neokidney. The Singapore-based startup specializes in sorbent technologies for the regeneration of dialysate and has been a collaborator of Nextkidney’s for six years. The combined team will prepare for a clinical trial in Singapore, followed by a European multicenter trial and CE mark submission in 2023. Financial terms of the deal were not disclosed.

Akili Interactive Inc. is the latest in a growing field of med-tech startups that are merging with special purpose acquisition companies as a backdoor path to an initial public offering. On Wednesday, the digital medicine company reported plans to combine with Social Capital Suvretta Holdings Corp. I in a deal valued at approximately $1 billion.

Smith & Nephew plc added new indications for use of its Pico 7 and Pico 14 single-use negative pressure wound therapy (sNPWT) systems. The FDA cleared the London-based device maker’s systems for reducing the incidence of both deep and superficial incisional surgical sites and dehiscence. Smith & Nephew’s Pico 7Y system, which treats two wounds simultaneously, was also cleared to aid in the reduction of the incidence of superficial incisional SSIs for high-risk patients in class I wounds, post-operative seroma and dehiscence.